Document Detail

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.
MedLine Citation:
PMID:  22077466     Owner:  NLM     Status:  In-Data-Review    
A number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal drug delivery systems have the ability to provide a dual mechanism of activity where tumor accumulation can deliver high local concentrations of the drug at the site of action with concomitant slow release of the drug from carriers in the blood compartment that results in antivascular effects, similar to that achieved when dosing frequently at low levels. Although this dual mechanism of activity may be linked to other lipid nanoparticle formulations of anticancer drugs, this article summarizes the evidence supporting direct (cytotoxic) and indirect (antivascular) actions of a liposomal formulation of irinotecan.
Dawn N Waterhouse; Donald Yapp; Maite Verreault; Malathi Anantha; Brent Sutherland; Marcel B Bally
Related Documents :
21907796 - Overcoming cellular multidrug resistance using classical nanomedicine formulations.
22169256 - Toxic epidermal necrolysis: review of pathogenesis and management.
7912646 - A sensitive assay for taxol and other microtubule-stabilizing agent.
3473056 - Cytotoxicity of combinations of prostaglandin d2 (pgd2) and antitumor drugs for b16 mel...
489196 - Studies on kinetics of anturan excretion in man.
10386226 - Kinetic aspects of drug disposition in the lungs.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nanomedicine (London, England)     Volume:  6     ISSN:  1748-6963     ISO Abbreviation:  Nanomedicine (Lond)     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101278111     Medline TA:  Nanomedicine (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  1645-54     Citation Subset:  IM    
BC Cancer Agency, Department of Experimental Therapeutics, 675 West 10th Avenue, Vancouver BC Canada, V5Z 1L3.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Design of self-assembling peptides and their biomedical applications.
Next Document:  Laminectomy, durotomy, and piotomy effects on spinal cord intramedullary pressure in severe cervical...